The most consequential concept for anyone selling or buying research chemicals is intended use, because it is the concept that decides whether an article is a research material or an unapproved drug. It is also routinely misunderstood as something a label controls.
The basic principle
Under the Federal Food, Drug, and Cosmetic Act, an article is a drug if it is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or if it is intended to affect the structure or any function of the body. The operative word is intended, and intent here is not a private state of mind. It is established from objective evidence — principally from how the seller represents the article.
What counts as evidence
The category is wider than most sellers assume, and it includes:
- Product descriptions. Any statement about effects on a body.
- Marketing material of every kind, including social posts and email.
- Blog and educational content published by the seller.
- Testimonials and reviews the seller publishes. A review describing personal use, displayed on the seller’s own site, is a representation by the seller. This is one of the largest and least-recognised exposures in this market.
- Preparation, handling and dosing guidance. Instructions describing how a person would prepare or administer material describe a person using it.
- Customer support correspondence. An answer given by email is evidence in the same way a web page is.
- Metadata and search targeting. Content assembled to reach an audience seeking a use is evidence about the intended audience.
What a disclaimer does and does not do
A research-use-only statement is consistent evidence when the rest of the presentation supports it. It does not override contrary evidence. A page that describes an outcome and then disclaims human use has produced evidence on both sides, and the disclaimer is the weaker of the two because the substantive claim is the one an audience acts on.
Why a supplier’s refusals are informative
Read against this framework, a supplier who declines to discuss effects, declines to advise on preparation, restricts who may purchase and groups its catalogue by receptor system rather than by outcome is not being evasive. It is behaving consistently with the category it claims to sell in. A supplier who does the opposite is generating evidence against its own designation, and doing it in public where it is indexed and archived.
What this means for your records
If your institution buys research chemicals, the supplier’s public position is part of your supply-chain risk. It is reasonable to keep a note in a supplier file recording how the supplier presents its materials, because that is the factor most likely to interrupt supply.
Our own position: we make no claim about what any compound does, we provide no preparation, handling or dosing guidance, we restrict sale to research institutions, licensed researchers, universities and laboratory R&D purchasers, and we publish an independent analysis per product rather than a story about it. This is a description of practice, not legal advice; your compliance office is the right authority on your own obligations.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.